Recent Updates
Recently added Catalysts

Chronic Myelogenous Leukemia: two biotech companies racing to a treatment

OncologyConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$3.0Buniverse median $1.20B
Allocated capital$2.4B$6.0B competing
Phase 3 or filed10 mid, 1 early
Pure plays0this indication only
Capital rank81/299crowding rank 80

Chronic Myelogenous Leukemia is a two-horse race: Ascentage Pharma Group International Unsponsored (AAPG, $1.6B) against Enliven Therapeutics (ELVN, $4.4B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $2.4B of allocated capital sits on the pair.

ELVN carries 73% of the $6.0B competing here, so the pair is far from evenly matched.

$2.4B of allocated capital sits in Chronic Myelogenous Leukemia, ranking it 81st of 299 indications by the money committed to it.

Companies developing drugs for Chronic Myelogenous Leukemia 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AAPGAscentage Pharma Group International UnsponsoredolverembatinibPhase 32$1.6BNo9No dated event
ELVNEnliven TherapeuticsELVN-001Phase 12$4.4BNo2 9 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ELVN holds 73% of the $6.0B competing in this indication.

Why Chronic Myelogenous Leukemia is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Chronic Myelogenous Leukemia has 2 competitors and a median of $3.0B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Pancreatic Cancer9 companies · $2.4B · median $371MKnife fightMelanoma4 companies · $2.3B · median $2.6BConcentrated betGastrointestinal Stromal Tumor3 companies · $2.3B · median $1.6BConcentrated betMeningioma3 companies · $2.5B · median $14.7BConcentrated betBreast Cancer10 companies · $2.7B · median $288MKnife fightProstate Cancer6 companies · $2.7B · median $1.1BKnife fightNon-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontestedIDH-Mutant Astrocytoma, Grade 23 companies · $2.0B · median $2.5BConcentrated bet

Chronic Myelogenous Leukemia pipeline questions

Which biotech companies are developing drugs for Chronic Myelogenous Leukemia?

Ascentage Pharma Group International Unsponsored (AAPG, olverembatinib, Phase 3); Enliven Therapeutics (ELVN, ELVN-001, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Chronic Myelogenous Leukemia.

How advanced is the Chronic Myelogenous Leukemia pipeline?

Of the 2 clinical-stage programmes in Chronic Myelogenous Leukemia, 1 is in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Which company leads the Chronic Myelogenous Leukemia field?

ELVN is the largest developer in Chronic Myelogenous Leukemia, holding 73% of the $6.0B of market capitalisation competing in the indication. The median competitor is worth $3.0B.

When is the next Chronic Myelogenous Leukemia catalyst?

The next dated catalyst in Chronic Myelogenous Leukemia is ELVN on 9 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map